New York-based Balchem Corporation has signed a definitive agreement to acquire Norwegian Vitamin K2 supplier Kappa Bioscience AS for approximately US$340 million.
A new review paper lays out the need for adequate vitamin K2 levels in children. Deficiency is associated with a range of issues including a predisposition toward cardiovascular disease and poor bone health.
